Skip to content

MassBio

Massachusetts Biotechnology Council

Open search form
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
  • Resources
    • 2023 Diversity, Equity, & Inclusion Report
    • 2023 Industry Snapshot
    • 2022 Massachusetts Biopharma Funding Report
    • 2022 MA Life Sciences Workforce Analysis Report
    • Economic Development
    • Biopharma Startup Toolkit
    • Career Center
    • MassBioEd
  • Events
    • Events Calendar
    • Overview of Events
    • Get Involved
  • Membership
    • Member Directory
    • Benefits of Membership
    • Savings and Rewards
    • Member News
    • Become a Member
    • Member Rates
    • Pay Company Dues
  • Savings & Rewards
    • MassBioEdge
  • Conference Center
    • MassBioHub
  • Programs
    • Bioversity at Southline Boston
    • State of Possible 2025 Report
    • Diversity, Equity, and Inclusion
    • Policy & Advocacy
    • Partnering Opportunities
    • MassBioDrive
    • Digital Health
    • BioReady Communities
  • About Us
    • About Us
    • News & Thought Leadership
    • Sponsorship Opportunities
    • Staff
    • Board of Directors
    • FAQs
    • Contact Us
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
Open search form

Member Directory

Click to Open Main Menu

Arietis Pharma

Life Sciences | Drug Development
Boston, MA 617-286-2165 Website

Overview

Arietis Corp. is a Boston-based biotechnology company focused on the discovery and development of novel antimicrobial agents. Our drug discovery pipeline focuses on sterilizing antibiotics that target Staphylococcus aureus, a leading cause of nosocomial and community acquired infections, and Helicobacter pylori, a cause of gastric ulcers and cancer. A newer discovery platform involves using synthetic biology to manipulate the human gut microbiome to improve human health and cure disease.

Pathogenic bacteria continually develop and spread resistance, yet the antibacterial armamentarium is increasingly limited. Founded in 2006, Arietis bridges an important gap in antimicrobial drug discovery and technology development. Arietis has forged productive alliances and partnerships within the biotechnology community as we advance our capacity to develop effective drug products. Arietis is committed to building value for its partners and shareholders, and we are well positioned to capitalize on the growing antimicrobial market. We are committed to providing innovative solutions for the problem of persistent infection, thereby decreasing the overall burden on healthcare worldwide.

The company was created based on technology invented by its founder, Professor Kim Lewis, Director of the Antimicrobial Center at Northeastern University, for which the company has obtained exclusive, world-wide licenses.

See all Members

Massachusetts Biotechnology Council

700 Technology Square, 5th Floor
Cambridge, MA 02139
617.674.5100

  • Contact
  • Privacy Policy
  • Fulfillment Policy
  • © 2024 All Rights Reserved